Stockwinners Market Radar for September 22, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:22 EDT Booz Allen awarded $151M U.S. Army contract - Booz Allen Hamilton was awarded a $150,949,292 cost-plus-fixed-fee contract for technology, innovation, and data engineering research and development; and disruptive intelligence, surveillance, and reconnaissance, science and technology research and development.

17:20 EDT Boeing awarded $221M U.S. Navy contract - The Boeing Co. is awarded $221,366,000 for a ceiling-priced, undefinitized contract action, delivery order N00383-23-F-YY36 under previously awarded basic ordering agreement for the procurement of seven various configurations of flight control surfaces spares used on the F/A-18 E/F and EA-18G aircraft. All work will be performed in St. Louis, Missouri, and work is expected to be completed by December 2029.

17:17 EDT Fluor Marine Propulsion awarded $1.36B U.S. Navy contract - Fluor Marine Propulsion is awarded a $1,362,922,002 cost-plus-fixed-fee modification to previously awarded contract N00024-18-C-2130 to exercise the fiscal 2024 options for Naval Nuclear Propulsion work at the Naval Nuclear Laboratory.

17:01 EDT Vicarious Surgical receives continued listing standard notice from NYSE - Vicarious Surgical announced that on September 20, 2023, it received a notice from the New York Stock Exchange that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the company's Class A common stock was less than $1.00 per share over a consecutive 30 trading-day period. The Notice does not result in the immediate delisting of the company's Class A common stock from the NYSE. The company intends to respond to the NYSE within ten business days of receipt of the Notice affirming its intent to cure the stock price deficiency and to return to compliance with the NYSE continued listing standard. Pursuant to the NYSE's rules, the company has a six-month period following receipt of the Notice to regain compliance with the NYSE's minimum share price requirement.

16:50 EDT MacroGenics, Aventis mutually terminate Royalty Purchase Agreement - As previously announced, on March 8, 2023, MacroGenics (MGNX) entered into a Purchase and Sale Agreement with DRI Healthcare Acquisitions LP, a wholly owned subsidiary of DRI Healthcare Trust, for the sale to DRI of the company's single-digit royalty interest on global net sales of TZIELD under the company's Asset Purchase Agreement dated May 7, 2018, as amended, with Provention Bio. The company retained its other economic interests related to TZIELD, including future potential regulatory and commercial milestones. Further, as previously disclosed, on April 27, 2023, the company entered into an agreement with DRI and Aventis, a subsidiary of Sanofi S.A. (SNY), whereby the company consented to the sale of the Royalty Interest and certain related milestone payment obligations under the Royalty Purchase Agreement to Aventis. The Tripartite Agreement eliminated the company's obligation to deliver payments to DRI related to the Royalty Interest and all of the company's other obligations under the Royalty Purchase Agreement. The Royalty Interest will be paid directly to Aventis by Provention Bio. The company is also eligible to receive a $50M milestone payment if TZIELD achieves a certain level of net sales under the Asset Purchase Agreement. In addition the company remains eligible to receive a 50% share of the royalty on global net sales of TZIELD above a certain annual threshold. On September 19, 2023, the company and Provention Bio entered into an amendment of the Asset Purchase Agreement to incorporate the Sales Milestone Payment obligation from the Royalty Purchase Agreement, along with a guaranty of such obligation by Sanofi and to eliminate any obligation for Provention Bio to pay the Royalty Interest to the company. On September 19, 2023, the company and Aventis concurrently entered into a Mutual Termination Agreement terminating the Royalty Purchase Agreement.

16:31 EDT Vaccinex announces 1-for-15 reverse stock split - Vaccinex announced that it will effect a 1-for-15 reverse stock split of its issued common stock, effective at 5:00 p.m. Eastern Time on Monday, September 25. Beginning Tuesday, September 26, the company's common stock will trade on a split-adjusted basis. The company's Board of Directors implemented the reverse stock split with the objective of regaining compliance with the $1.00 minimum bid price requirement of The Nasdaq Capital Market. The company has until October 9 to comply with this requirement. To evidence compliance with this requirement, the closing bid price of the company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days by October 9. The company's shares of common stock will continue to trade on The Nasdaq Capital Market under the symbol "VCNX." The new CUSIP number for the company's common stock post-reverse stock split is 918640202.

16:18 EDT Bird Global trading halted, news pending

16:06 EDT AutoNation names Jeff Parent as COO - AutoNation is delighted to announce the appointment of Jeff Parent as its new COO. With extensive experience in senior executive roles spanning sales, supply chain management, and business strategy, Parent brings a wealth of expertise to lead the company's operational and strategic initiatives. Parent's start date is expected to be October 16. Parent's most recent role was as President and General Manager at Gulf States Toyota, one of the world's largest independent distributors of Toyota vehicles and parts. AutoNation also announces that Steve Kwak, COO, Franchised Business, will be leaving the company to pursue another opportunity. Steve's last day will be September 30.

15:57 EDT HomeStreet says board determined DUS price proposal was inadequate - HomeStreet responded to Blue Lion Capital Letters to Shareholders. "In several recent letters to our Board of Directors and shareholders written by Chuck Griege, managing partner of Blue Lion Capital, he has proposed the Company sell our FNMA Delegated Underwriter and Servicer business (per Griege the "DUS license") and related loan servicing portfolio (together our "DUS Business") and utilize the gain and proceeds to sell certain low yielding loans and reduce borrowings," said HomeStreet chairman and CEO Mark Mason. "In these letters Mr. Griege has stated that the value of our DUS Business is "between $100 million and $150 million." In his most recent letter Mr. Griege stated that "HMST has received at least one letter of intent from an interested buyer for the DUS license and MSRs and believe[s] that it meets the [$100 million] valuation threshold. . ." On September 15, 2023, the Company received an unsolicited non-binding written proposal to purchase our DUS Business (including our related loan servicing portfolio carried at $32 million on June 30, 2023) from a third party group for $57 million (the "DUS Purchase Proposal"). One of the members of this third party group was recommended to us by Mr. Griege in a prior letter to our Board of Directors. Our Board of Directors and management have analyzed the DUS Purchase Proposal and determined that the price proposed was inadequate in relation to the resulting benefit and value of the DUS Business to our Company and as such a sale of our DUS Business at this price was not in the best interests of the Company."

14:42 EDT BCBSM modifying weight loss drug coverage to require 'lifestyle modifications' - Blue Cross Blue Shield of Michigan, or BCBSM, and Blue Care Network announced that starting Oct. 1, 2023, the groups will change the prior authorization approval criteria for commercial PPO and HMO plans for weight loss drugs that include Contrave, Evekeo, Qsymia, Saxenda, Wegovy and Xenical. The notice dated September 21 states: "Starting in October, members will be required to make lifestyle modifications for at least six months before they're approved for weight loss drug therapy. Examples of lifestyle interventions include active participation in weight loss programs, such as Noom and WeightWatchers or active participation in other lifestyle modifications, such as diet and exercise, under the supervision of their provider." WW (WW) is the maker and provider of the WeightWatchers program. Novo Nordisk (NVO), Eli Lilly (LLY) and Amgen (AMGN) market or are developing weight loss drugs. Reference Link

13:14 EDT Coherent jumps after Reuters says Japanese firms considering investment - Coherent (COHR) shares are jumping after Reuters' Milana Vinn reported that the company has attracted interest from four Japanese conglomerates for an investment in its silicon carbide business at a valuation of as much as $5B. Denso (DNZOY), Hitachi (HTHIY), Mitsubishi Electric (MIELY) and Sumitomo Electric (SMTOY) have held talks about taking a minority stake in Coherent's silicon carbide business, according to the the source, which said Coherent may accept more than one of these companies as investors in the silicon carbide division at a valuation of between $4B-$5B. The report, which cites a person familiar with the matter, said such an investment would alleviate the financial burden for Coherent as it plans to invest $1B over the next 10 years to expand its production of silicon carbide wafers used in electric vehicles. Following the report, shares of Coherent are up $3.17, or 11%, to $32.09.

13:01 EDT Baker Hughes reports U.S. rig count down 11 to 630 rigs

12:21 EDT Axcella Health trading halted, volatility trading pause

12:16 EDT Penske says binding offer for Pendragon not certain - Pendragon today issued an announcement confirming that PAG International, a wholly owned subsidiary of Penske Automotive Group, together with Hedin Mobility Group, submitted a revised non-binding proposal to jointly acquire the entire issued and to be issued share capital of Pendragon not already owned by Hedin Mobility Group for 32 pence per share, in cash. Following its receipt of the revised proposal, the board of Pendragon publicly announced that they intend to consider the proposal and will consult with their shareholders and provide an update in due course. "There can be no certainty that PAG International and Hedin Mobility Group will make a binding offer for Pendragon, or as to the terms of any such offer. The Company makes no representation as to the accuracy or completeness of the Pendragon Announcement, which was filed without the consent of PAG International and Hedin Mobility Group," Penske said in a regulatory filing.

12:00 EDT Emergent BioSolutions falls -5.8% - Emergent BioSolutions is down -5.8%, or -20c to $3.24.

12:00 EDT WeWork falls -5.9% - WeWork is down -5.9%, or -21c to $3.36.

12:00 EDT Lifezone Metals rises 11.1% - Lifezone Metals is up 11.1%, or $1.33 to $13.33.

11:56 EDT Bolt Biotherapeutics treatment of gastric cancer granted orphan designation - Bolt Biotherapeutics' trastuzumab biosimilar conjugated with TLR7/8 via a non-cleavable linker was granted FDA orphan designation as a treatment of gastric cancer, including gastroesophageal junction cancer, according to a post to the agency's website. Reference Link

11:51 EDT Connexa Sports Technologies announces 1-for-40 reverse stock split - Connexa Sports Technologies will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-40. The reverse stock split will become effective on September 22, 2023. The Company's common stock will begin trading on a post-split basis at the market open on September 25, 2023, under the Company's existing trading symbol "CNXA", with the new CUSIP number, 831445309. The reverse stock split is part of the Company's plan to regain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits. The reverse stock split was approved by the Company's stockholders at the Company's Special Meeting of Stockholders held on September 13, 2023, to be effected in the discretion of the Company's board of directors within approved parameters. The final ratio was approved by the Company's board of directors on September 13, 2023. The reverse stock split reduces the number of shares of the Company's outstanding common stock from approximately 29.5 million shares to approximately 740,000 shares.

11:47 EDT Morphic weakness attributed to posting of MORF-057 trial abstract - An abstract posted to the site of UEG Week, the United European Gastroenterology Week meeting in Copenhagen, is being attributed as the reason for weakness this morning in shares of Morphic, which are down $18.24, or 35%, to $33.16. The abstract states in part: "MORF-057 is an orally dosed small molecule designed to selectively inhibit the alpha4beta7 integrin, avoiding the need for parenteral administration. This Phase 2a open label study aimed to assess the safety, tolerability, pharmacokinetics, and efficacy of MORF-057 dosed 100 mg twice daily for induction treatment in adults with moderately to severely active ulcerative colitis, UC... Of the 35 patients in the Full Analysis Set, 31/35 (89%) completed the 12-week induction Period. The mean baseline modified Mayo score was 6.7 and the mean RHI score was 22.7. At Week 12, the primary endpoint of the study was met with a mean reduction in the RHI score of - 6.4. For the secondary endpoint of change from baseline in the modified Mayo Clinic score, a change of -2.3 points was observed. 25.7% of patients achieved mMCS clinical remission. The proportion of patients achieving a mMCS clinical response was 45.7% and endoscopic improvement was achieved in 25.7% of patients." Reference Link

11:35 EDT UAW expands 'Stand Up Strike' against General Motors and Stellantis - UAW President Shawn Fain announced on Facebook Live that the union, at noon today, will expand its Stand Up Strike against General Motors (GM) and Stellantis (STLA) at 38 locations across 20 states. "On Monday, Fain had announced that the union would expand its Stand Up Strike against automakers that did not make substantial progress toward a fair agreement. Neither company did. Approximately 5,600 Big Three workers will join the approximately 13,000 who are already on strike. The union is continuing to strike Ford's Michigan Assembly Plant in Wayne, Mich., but is not expanding its strike against the Dearborn-based automaker. The UAW and Ford did make substantial progress in bargaining over the last week," the union stated. Reference Link

10:57 EDT Ford says 'working diligently with the UAW to reach a deal' - Ford issued the following response to the UAW strike announcement: "Ford is working diligently with the UAW to reach a deal that rewards our workforce and enables Ford to invest in a vibrant and growing future. Although we are making progress in some areas, we still have significant gaps to close on the key economic issues. In the end, the issues are interconnected and must work within an overall agreement that supports our mutual success." Reference Link

10:46 EDT Xcel Energy announces grant of up to $70M from DOE - Xcel Energy announced that it has received a grant of up to $70M from the U.S. Department of Energy, or DOE. The award will partially fund two long duration energy storage systems in Minnesota and Colorado. "As we explore cutting-edge technologies to accelerate our journey toward 100% carbon-free electricity, we are committed to also keep our services affordable for our customers. The Department of Energy grant provides crucial financial support for projects that will provide reliable, low-cost renewable energy to the communities we serve," said Bob Frenzel, chairman, president and CEO of Xcel Energy.

10:39 EDT LZM Stock trading halted, volatility trading pause

10:32 EDT Leafly files legal challenge to Adult Use Regulations in New York - Leafly, Stage One Dispensary in Rensselaer, New York, and an individual consumer, jointly filed a legal challenge to certain portions of the recently adopted Adult Use Regulations in New York. On Thursday, the New York Attorney General's Office agreed to a stay, and the court entered an order to that effect, which blocks the enforcement of the challenged regulations against Leafly and fully operational licensed cannabis dispensaries in New York State. Leafly is the only third-party platform that the stay expressly allows to continue offering paid advertising services, display retailer product pricing, and transmit orders to licensed cannabis retailers in New York. As a result, while the stay is in effect, licensed retailers in New York will continue to have access to important advertising and marketing tools to help them succeed in the legal cannabis market, and provide consumers with access to critical information as they make purchasing decisions. The lawsuit alleges that New York's Office of Cannabis Management unfairly targeted so-called "third-party platforms" in a misguided attempt to restrict the manner in which retailers may market or promote their business and products, and prevent price-shopping consumer behaviors. Leafly believes, and the lawsuit alleges, that the adoption of these regulations by the state is both arbitrary and capricious and a violation of the United States and New York constitutions.

10:30 EDT ADiTx Therapeutics trading resumes

10:23 EDT Farmmi announces approval of 1-for-8 ordinary share consolidation - Farmmi announced that at the company's shareholder meeting on September 21 shareholders approved the previously proposed consolidation of the company's ordinary shares at the ratio of one-for-eight with the market effective date of September 25. Beginning with the opening of trading on September 25, the company's ordinary shares will trade on the Nasdaq Capital Market on a split-adjusted basis, under the same symbol "FAMI."

10:20 EDT ADiTx Therapeutics trading halted, volatility trading pause

10:12 EDT MasterCard issues response to congressional letter on CCCA - Mastercard wrote to several members of the U.S. Congress this week to highlight the harms the Credit Card Competition Act would bring to consumers, businesses of all sizes and financial institutions. The letter explains how the Credit Card Competition Act would remove consumer choice, erode security, eliminate rewards, and prevent small businesses from investing in their future. The letter says in part: "Mastercard is not increasing US interchange rates this fall. Mastercard is not raising network fees in the US required for the processing of transactions this fall. The payments industry has never been more competitive. Electronic payments empower consumers, allow merchants of all sizes to thrive, and strengthen the American economy. Mastercard's technology protects consumers from fraud and keeps them safe." The letter further says: "Competition has made this country great. It has inspired individuals and companies to think big and drive innovation. However, the Credit Card Competition Act will thwart the competition you seek to protect. The legislation will remove consumer choice, erode security, eliminate rewards, and dramatically prevent small businesses from investing in their future. Competition is threatened when policy is made in the absence of facts." Reference Link

10:00 EDT IHS Holding falls -4.6% - IHS Holding is down -4.6%, or -22c to $4.60.

10:00 EDT Noah Holdings rises 7.8% - Noah Holdings is up 7.8%, or 92c to $12.79.

10:00 EDT Lifezone Metals rises 16.7% - Lifezone Metals is up 16.7%, or $2.00 to $14.00.

09:53 EDT PolyPid trading resumes

09:47 EDT Direxion Daily Junior Gold Miners Index Bear 3x Shares falls -3.7% - Direxion Daily Junior Gold Miners Index Bear 3x Shares is down -3.7%, or -27c to $7.06.

09:47 EDT New Oriental Education rises 6.0% - New Oriental Education is up 6.0%, or $3.23 to $57.22.

09:47 EDT XPeng rises 6.6% - XPeng is up 6.6%, or $1.05 to $16.94.

09:35 EDT European Commission re-imposed EUR 376M fine on Intel - The European Commission said it has re-imposed a fine of around EUR 376.36M on Intel for a "previously established abuse of dominant position" in the market for computer chips called x86 central processing units. "Intel engaged in a series of anticompetitive practices aimed at excluding competitors from the relevant market in breach of EU antitrust rules," the agency said in a statement. This decision is without prejudice to the Commission's pending appeal against the General Court's annulment of its 2009 finding of an infringement as regards Intel's conditional rebates. Reference Link

09:26 EDT Instacart appoints Ravi Gupta to board of directors - Instacart announced that Ravi Gupta, Partner at Sequoia Capital, has joined the company's Board of Directors. Gupta is a seasoned technology executive with more than 20 years of experience in business operations and finance. He brings to the Board a deep and nuanced understanding of Instacart's business, having served as the company's CFO from 2015 to 2019, and from 2016 to 2019, also served as COO.

09:12 EDT Standard Lithium reports cash totaling C$59.6M as of June 30 - "As we conclude fiscal year 2023, we take pride in our achievements," said Robert Mintak CEO of Standard Lithium. "Over the past year, and with a particularly robust set of activities in our fiscal Q4, we conducted extensive drilling, resource development and engineering work. This effort culminated in the successful delivery of the Preliminary Feasibility Study for the South West Arkansas Project and the Definitive Feasibility Study for the Phase 1A Project at the LANXESS South Plant. These milestones reaffirm our commitment to concurrent project advancement, with the aim of delivering commercial production in 2026 and 2027. Recent media reports have highlighted the interest of global energy companies' in lithium, specifically brine resources, and the Smackover Formation as their preferred resource, validating our work. Building upon our established strategic partnerships with industry leaders like Koch and LANXESS, we are receptive to and continuously exploring opportunities to forge synergistic collaborations and further de-risk our projects. Additionally, we are expanding our presence in East Texas, cementing our dedication to exploring and unlocking the full potential of this resource-rich region. While lithium prices have retreated from record highs earlier this year, it's noteworthy that demand for responsibly produced U.S. lithium has surged. Our engagement with global OEMs, battery companies, and strategic parties has accelerated, underscoring the growing demand for ethically sourced lithium. In collaboration with our finance and policy advisors, we are actively exploring non-dilutive capital sources, including those made available through the Inflation Reduction Act and other administration programs, to expedite our efforts. We are working diligently to seize opportunities and leverage our expertise to shape the growth and sustainability of the lithium sector."

09:09 EDT Ohmyhome hosts Hawaii state housing delegation in Singapore - Ohmyhome had the honor of hosting Sen Stanley Chang and his delegation consisting of policy-makers, non-profit leaders and private sector members across the United States at their Singapore Office on September 22, 2023. This visit aimed to explore and gain valuable insights into the Singaporean housing market, with a focus on the differences between purchasing new HDB flats, resale of HDB flats, and private properties, as well as understanding the respective market performance of each category.

09:06 EDT Conduit Pharmaceuticals, Murphy Canyon complete business combination - Conduit Pharmaceuticals and Murphy Canyon Acquisition announced the completion of the previously announced business combination. Conduit expects to commence trading on September 25, 2023, under ticker symbol "CDT" for its common stock on The Nasdaq Global Market and ticker symbol "CDTTW" for its warrants on The Nasdaq Capital Market. At the debut of trading, there will be a pro forma enterprise value of approximately $720 million. Existing Conduit Pharmaceuticals shareholders will own approximately 90% of the combined company's common stock issued and outstanding as of the closing. Immediately prior to completion of the Transaction, MURF closed the previously announced investment by a single institutional investor, which purchased $20.0 million of MURF's units at a price of $10.00 per unit in a private placement. Each unit consisted of one share of common stock and one warrant to purchase one share of common stock. The warrants have an exercise price of $11.50, are exercisable after 30 days after the completion of the business combination and expire five years after the completion of the Transaction. Together, the Transaction and the Offering, provide Conduit with approximately $20 million, after giving effect to Murphy Canyon stockholder redemptions and before payment of Transaction and Offering expenses. The Transaction was completed on September 22, 2023. In connection with the completion of the Transaction, MURF changed its name to Conduit Pharmaceuticals Inc. The shares of common stock of the combined company are expected to begin trading on September 25, 2023, under the new ticker symbol "CDT" on The Nasdaq Global Market and the warrants under the new ticker symbol "CDTTW" on The Nasdaq Capital Market.

09:04 EDT BIMI International Medical's Phenix Bio appoints Hao Mu as distributor - BIMI International Medical announced its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company, as its exclusive distributor responsible for the distribution of Phenix's 17 herbal supplements throughout the Association of Southeast Asian Nations 10 member countries. Pursuant to the terms of a sales agreement entered on September 20, 2023, Hao Mu Pte. Ltd., as Phenix's exclusive distributor for the 10 ASEAN member countries, must make annual purchases of at least $5 million in order to maintain its exclusive distributor status. The parties also agreed to explore an opportunity where Phenix may acquire equity interests in Hao Mu if Hao Mu meets certain business, revenue and other criteria as mutually agreed upon by both parties. Under the terms of this agreement, Phenix's comprehensive portfolio of high-quality herbal supplements will be made available to consumers in ASEAN countries through Hao Mu's well-established distribution channels and network.

09:02 EDT Ligand's partner Jazz Pharmaceuticals receives EC approval for Enrylaze - Ligand Pharmaceuticals (LGND) announced that its partner Jazz Pharmaceuticals plc (JAZZ) has been granted marketing authorization by the European Commission, EC, for Enrylaze for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. "We congratulate our partner Jazz on its receipt of approval for Enrylaze from the European Commission, expanding the market opportunity for one of our key commercial-stage products," said Todd Davis, CEO of Ligand Pharmaceuticals. "Jazz has executed on a successful launch of the product in the U.S., and we look forward to contributions from sales in the European Union." Ligand is eligible to receive milestone payments and tiered low- to mid-single digit royalties based on worldwide net sales of any products resulting from its collaboration with Jazz, including Rylaze.

08:49 EDT Abbott completes acquisition of Bigfoot Biomedical - Abbott announced it has completed the acquisition of Bigfoot Biomedical, a developer of smart insulin management systems for people with diabetes. Pursuant to the terms of the merger agreement, upon completion of the acquisition, Bigfoot became a wholly owned subsidiary of Abbott. Financial terms were not disclosed.

08:36 EDT Rocky Mountain Chocolate names Scott Ouellet SVP, manufacturing, supply chain - Rocky Mountain Chocolate Factory announced that Scott Ouellet has been appointed to the role of Senior Vice President, Manufacturing and Supply Chain, effective September 18, 2023. Mr. Ouellet has acted as a Senior Supply Chain Advisor to RMCF since October 2022. Prior to his engagement with RMCF, Mr. Ouellet served as a supply chain advisor for the leadership team at Wyandot Snacks.

08:34 EDT Bitcoin Depot announces $10M share repurchase program - Bitcoin Depot announced that its Board of Directors has authorized a share repurchase program pursuant to which the Company is authorized to repurchase up to $10 million of outstanding shares of its Class A common stock beginning immediately and continuing through and including June 30, 2024.

08:33 EDT Bitcoin Depot announces $10M share repurchase program - Bitcoin Depot announced that its Board of Directors has authorized a share repurchase program pursuant to which the Company is authorized to repurchase up to $10 million of outstanding shares of its Class A common stock beginning immediately and continuing through and including June 30, 2024.

08:26 EDT GigaCloud enters into three new warehouse leases in September - GigaCloud Technology has entered into three new warehouse leases in September 2023. These warehouses are scheduled to commence operations in October 2023, resulting in 24 total warehouses globally for the Company. The additional capacity need was fueled by further expansion of GigaCloud's B2B marketplace and ensures customers receive the logistical support they need to run their businesses. Two of these warehouses will be situated in the U.S. in Savannah, Georgia, and Rancho Cucamonga, California, covering a combined area of approximately 784,300 square feet, resulting in a 20.7% increase of the warehousing space in the U.S. The third warehouse, located in Bremen, Germany, will encompass a total space of approximately 110,400 square feet, marking a 47.8% increase of the total warehouse areas in Germany. These strategically placed warehouses will primarily serve as key distribution centers for GigaCloud's large parcel merchandise, ensuring efficient storage, processing, and distribution of products. Following the addition of three new warehouses, totaling approximately 894,700 square feet, the GigaCloud global warehouse network now spans across North America, Europe, and Asia, encompassing a total area of approximately 5.2 million square feet.

08:10 EDT Yunhong CTI to change corporate name to Yunhong Green CTI - Yunhong CTI has changed its corporate name to Yunhong Green CTI LTD. The Company's stockholders approved this action during the August 28, 2023 annual meeting of stockholders. The Company's shares will start trading under its new name and stock ticker symbol, 'YHGJ', effective as of market open on September 25, 2023. No action by the Company's shareholders is required with respect to the ticker symbol change. The Company's CUSIP number will remain unchanged.

08:06 EDT Alzamend Neuro granted extension by Nasdaq panel to regain compliance - Alzamend Neuro announced that it received notice from the Nasdaq Hearings Panel of The Nasdaq Stock Market, which granted Alzamend's request for continued listing on The Nasdaq Capital Market, subject to Alzamend's satisfaction of the minimum $1.00 bid price requirement by November 15, 2023. The Hearings Panel granted Alzamend the extension based upon Alzamend's representations that it would, on or before September 29, 2023 obtain stockholder approval for and effect a reverse stock split at a ratio between 1:2 and 1:20 and on or before November 1, 2023, effect a reverse stock split, and thereafter maintain a $1.00 closing bid price for a minimum of ten consecutive business days. "We are pleased that Nasdaq has granted us this extension and intend to take the necessary steps to regain compliance with Nasdaq's minimum bid price requirement," said Stephan Jackman, Chief Executive Officer of Alzamend. "Our annual stockholder meeting is set for September 29, 2023, at which time we expect our stockholders will approve a reverse stock split. Presuming stockholder approval, we intend to expeditiously implement the split to maintain our Nasdaq listing."

08:05 EDT MariaDB plc receives NYSE continued listing standards notice - MariaDB announced that it was notified on September 19, 2023 by the New York Stock Exchange, NYSE, that the Company is not in compliance with Section 802.01B of the NYSE Listed Company Manual because the Company's average global market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, the Company's last reported stockholders' equity was less than $50 million.

08:03 EDT Neoleukin Therapeutics announces 1-for-5 reverse stock split - Neoleukin Therapeutics' Board of Directors has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-for-5. The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. Neoleukin's common stock will begin trading on a post-reverse stock split basis on September 25, 2023, under Neoleukin's existing trading symbol "NLTX" with a new CUSIP number 64049K203. The reverse stock split is part of Neoleukin's plan to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The reverse stock split was approved by Neoleukin's stockholders at the Company's 2023 Annual Meeting of Stockholders held on June 8, 2023, to be effected in the Board's discretion within approved parameters. The final reverse stock split ratio was approved by the Board on August 30, 2023. The reverse stock split reduces the number of shares of the Company's outstanding common stock from approximately 44,026,429 shares to approximately 8,805,285 shares and reduces the number of shares of the Company's authorized common stock from 100,000,000 to 20,000,000. As a result of the reverse stock split, proportionate adjustments will be made to the exercise prices and number of shares of Neoleukin's common stock underlying the Company's outstanding equity awards and prepaid warrants for common stock, as well as the number of shares issuable under the Company's equity incentive plan and employee stock purchase plan. There will be no change to the par value per share.

08:01 EDT United Airlines names Michael Leskinen as CFO - United Airlines announced that Michael Leskinen has been promoted to CFO and Executive Vice President. In his new role, he will oversee corporate finance, treasury, financial planning and analysis, tax, accounting, investor relations, procurement, internal audit, risk management and corporate strategy. Leskinen will also join the airline's Executive Team. Leskinen joined United in 2018 as managing director of Investor Relations and was promoted to vice president of Corporate Development and Investor Relations in 2019.

07:48 EDT Scilex reports consummation of purchase of shares owned by Sorrento - Scilex Holding Company (SCLX) on Thursday announced the consummation of the previously announced purchase of securities from Sorrento Therapeutics (SRNE). Pursuant to that certain Stock Purchase Agreement entered into on September 21, 2023, between Scilex and Sorrento, Scilex, through its wholly-owned subsidiary, acquired (i) all of the shares of Scilex common stock owned by Sorrento, (ii) all of the shares of Scilex preferred stock owned by Sorrento, and (iii) all of the warrants for the purchase of shares of Scilex common stock owned by Sorrento for aggregate consideration consisting of: (i) $110M; plus (ii) the assumption by the company of certain legal fees and expenses in the amount of approximately $12.25M; plus (iii) a credit bid of all amounts owed to Scilex under the junior secured debtor-in-possession financing facility provided by Scilex to Sorrento. Concurrently and in connection with the consummation of the Securities Transfer, Scilex assumed approximately $100 million in indebtedness of Sorrento owed to Oramed Pharmaceuticals (ORMP) by entering into a Securities Purchase Agreement with Oramed, pursuant to which, among other things, Scilex (i) issued to Oramed (A) a senior secured promissory note in the principal amount of $101,875,000, which is equal to the unpaid principal and accrued and unpaid interest, fees and expenses under Sorrento's $100 million senior secured debtor in possession term loan facility with Oramed, secured by a senior lien on substantially all of the Company's and its subsidiaries' assets, subject to certain exclusions, with an interest rate of SOFR +8.5%, and (B) warrants to purchase up to 13.0 million shares of Common Stock, subject to the terms and conditions set forth therein, each with an exercise price of $0.01 and each with restrictions on exerciseability, and (ii) caused to be transferred from its wholly-owned subsidiary to Oramed outstanding warrants previously held by Sorrento to purchase up to an aggregate of 4.0 million shares of Common Stock. "This transaction demonstrates our commitment to deliver long-term value to our shareholders and advance innovative non-opioid therapies for acute and chronic pain patients. Our talented team is dedicated in furthering improvements in the care of patients to enhance quality of life," said Jaisim Shah, President and CEO of Scilex.

07:46 EDT Pyxis Tankers to sell Pyxis Epsilon for $40.75M in cash - Pyxis Tankers has agreed to sell the vessel Pyxis Epsilon, a 2015 built 50,295 dwt. product tanker, for a sale price of $40.75M in cash to an unaffiliated buyer located in the United States. Completion of the vessel sale, which is subject to customary closing conditions, is expected to occur during the fourth quarter of 2023. After the repayment of the outstanding indebtedness secured by the vessel and the payment of various transaction costs, the Company expects to receive cash proceeds of approximately $26.4M, which would be used for general corporate purposes. Assuming completion of the vessel sale during the fourth quarter of 2023, the Company expects to recognize a non-cash gain from asset disposition of approximately $16.8M or $1.57 per current outstanding common share.

07:31 EDT Lovesac receives notice of non-compliance from Nasdaq - The Lovesac Company received a notice from the Listing Qualifications Staff of the Nasdaq Stock Market on September 18, 2023 stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended July 30, 2023 with the Securities and Exchange Commission. On September 8, 2023, the Company filed a Notification of Late Filing on Form 12b-25 indicating that the filing of the Quarterly Report would be delayed due to additional time being needed to prepare a restatement to the Company's financial statements for the fiscal year ended January 29, 2023 and the thirteen weeks ended April 30, 2023. The Restatements are more fully described in the Company's Current Report on Form 8-K filed on August 16, 2023. Under the Nasdaq Listing Rules, the Company has 60 calendar days to submit a plan to regain compliance. If Nasdaq accepts the Company's plan, Nasdaq can grant an exception of up to 180 calendar days of the Quarterly Report's original due date, which 180-day period would end on March 6, 2024, to regain compliance. If Nasdaq does not accept the Company's plan, then the Company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel. The Company is working diligently to finalize and file the Restatements and the Quarterly Report as soon as possible within the timeline prescribed by Nasdaq.

07:08 EDT Stingray Group renews normal course issuer bid - Stingray Group announced that the Toronto Stock Exchange has approved the renewal of its normal course issuer bid, authorizing Stingray to repurchase up to an aggregate 2,765,903 subordinate voting shares and variable subordinate voting shares representing approximately 10% of the "public float" of Subordinate Shares as at September 15, 2023. The net average daily trading volume for the six-month period preceding September 1, 2023 represents 19,893 Subordinate Shares. In accordance with TSX requirements, Stingray is entitled to purchase, on any trading day, up to a total of 4,973 Subordinate Shares representing 25% of this average daily trading volume. Stingray believes that the purchase of up to 2,765,903 Subordinate Shares under the NCIB is an appropriate use of its funds and a desirable investment for Stingray and, therefore, would be in the best interests of Stingray. By making such repurchases, the number of Subordinate Shares in circulation will be reduced and the proportionate interest of all remaining shareholders in the share capital of Stingray will be increased on a pro rata basis. Stingray may repurchase Subordinate Shares on the open market through the facilities of the TSX as well as through other alternative Canadian trading systems, from time to time, over the course of twelve months commencing September 27, 2023 and ending at the latest on September 26, 2024.

07:05 EDT Edible Garden rolls out fall floral, ornamental shipments from Michigan facility - Edible Garden has begun shipping fall ornamentals, grown in its Edible Garden Heartland facility in Grand Rapids, Michigan. Jim Kras, CEO, commented, "We are pleased to kick off shipments of tens of thousands of fall ornamentals from our new Edible Garden Heartland facility in Grand Rapids, Michigan, just in time for the fall gardening season. Our offerings include mums, a favorite from last year, and marigolds, a fresh addition for 2023. These plants are now being delivered to leading big-box stores throughout the Company's distribution network...We believe we are making the most of the expanded growing capacity that our Edible Garden Heartland facility provides, enhancing our ornamental business within our existing distribution network, as well as expanding our ornamental offerings to potential customers outside our network. We expect higher profit margins from ornamentals and believe that growing this business area will positively impact the Company's overall profitability."

07:02 EDT West Fraser Timber to sell two pulp mills in Western Canada - West Fraser Timber and Atlas Holdings announced the signing of a definitive agreement for the sale of West Fraser's Quesnel River Pulp mill in Quesnel, British Columbia and its Slave Lake Pulp mill in Slave Lake, Alberta to Atlas. Atlas owns and operates several pulp, paper and wood products businesses in Canada and the United States. The agreement announced today includes related woodlands operations and timber holdings in Alberta and a long-term fibre supply agreement for the Quesnel River Pulp facility. Upon closing of the transaction, the Quesnel River and Slave Lake pulp mills will be operated by Millar Western Forest Products, which joined the global Atlas family of manufacturing and distribution businesses in 2017. Combined total cash proceeds from the sale are $120 million. The transaction is anticipated to close following successful completion of customary regulatory reviews and satisfaction of customary closing conditions. West Fraser will provide a further update during its third quarter results conference call.

07:00 EDT Bristol Myers says Phase 3 CheckMate -77T trial met its primary endpoint - Bristol Myers Squibb announced the Phase 3 CheckMate -77T trial met its primary endpoint of improved event-free survival as assessed by Blinded Independent Central Review in patients with resectable stage IIA to IIIB non-small cell lung cancer. In a prespecified interim analysis, the perioperative regimen of neoadjuvant Opdivo with chemotherapy followed by surgery and adjuvant Opdivo showed a statistically significant and clinically meaningful improvement in EFS compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo. The safety profile of this Opdivo-based regimen was consistent with previously reported studies in NSCLC.

06:24 EDT AstraZeneca says Dato-DXd improved PFS in breast cancer trial - High-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan, or Dato-DXd, demonstrated a statistically significant and clinically meaningful improvement for the primary endpoint of progression-free survival, or PFS, compared to investigator's choice of chemotherapy in patients with inoperable or metastatic hormone receptor-positive, HER2-low or negative breast cancer previously treated with endocrine-based therapy and at least one systemic therapy, AstraZeneca announced. "A trend in improvement for the dual primary endpoint of overall survival was observed for datopotamab deruxtecan versus chemotherapy. Data for OS were not mature at this interim analysis and the trial will continue as planned to assess OS. The safety profile of datopotamab deruxtecan was consistent with previous clinical trials in breast cancer with no new safety signals identified. All grade interstitial lung disease rates were low. Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate being jointly developed by AstraZeneca and Daiichi Sankyo," the company stated.

06:19 EDT Life Time Group opens athletic country club in Connecticut - Life Time opened its first athletic country club in Connecticut with a nearly 52,000-square foot athletic country club and 10,000-square-foot rooftop beach club in downtown Stamford. The vertically integrated tower featuring 290 luxury residences for lease also opened, licensed under the Life Time Living brand. Membership to the athletic club is available to the public, while residents of Life Time Living receive a full-access membership to the connected Life Time Stamford, along with all 170 Life Time destinations across North America.

06:04 EDT Innate Pharma reports encore presentation of TELLOMAK Phase 2 study results - Innate Pharma announced an encore presentation of interim efficacy results from the TELLOMAK Phase 2 study in advanced Mycosis Fungoides according to updated guidelines at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023, being held September 21-23, 2023 in Leiden, the Netherlands. The data confirms clinical activity and favorable safety profile of lacutamab, an anti-KIR3DL2 antibody. The data were previously presented at the 17th International Conference on Malignant Lymphoma, in Lugano (Switzerland), in June 2023. As of March 4, 2022, data cutoff, patients in the KIR3DL2-expressing MF cohort received a median of 4 prior systemic therapies, and had a median follow-up of 12.2 months. In the KIR3DL2 non-expressing cohort, patients received a median of 4.5 prior systemic therapies and had a median follow-up of 13.8 months. Lymph Node assessment is an important component of staging and response assessment in CTCL. In a recent update to the Olsen 2011 guidelines, it was clarified that the pathological assessment of lymph nodes be limited to those that satisfy nodal lymphoma i.e. N3 designation. Based on these criteria, results showed that lacutamab produced an increased global objective response rate of 42.9% in patients with KIR3DL2 greater than or equal to 1% MF, including 2 complete responses and 7 partial responses. Clinical Benefit Rate remained unchanged at 85.7%. In Cohort 3, comprising 18 patients with KIR3DL2 less than 1% MF, findings remain unchanged.

05:58 EDT Pennsylvania American Water reaches agreement to acquire Audubon Water Company - Pennsylvania American Water announced that an agreement has been reached for it to acquire Audubon Water Company. Under the terms of the transaction, an affiliate of Pennsylvania American Water will merge with Audubon, with shareholders of Audubon Water receiving shares of AWK common stock in exchange for all of the issued and outstanding shares of Audubon, and subsequently, Audubon will merge into Pennsylvania American Water. The transaction values Audubon at approximately $8M. Audubon is a private, investor-owned system serving approximately 2,900 customers in Lower Providence Township, Montgomery County and is located directly between Pennsylvania American Water's existing Royersford and Norristown water systems.

05:52 EDT Seagen, Astellas Pharma report 'positive' results from Phase 3 EV-302 trial - Seagen (SGEN) and Astellas Pharma (ALPMY) announced positive topline results from the Phase 3 EV-302 clinical trial for PADCEV in combination with KEYTRUDA versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer, a form of bladder cancer that has spread to surrounding organs or muscles, or other parts of the body. The EV-302 trial enrolled patients with previously untreated la/mUC who were eligible for cisplatin- or carboplatin-containing chemotherapy regardless of PD-L1 status. The EV-302 study met its dual primary endpoints of overall survival and progression-free survival, compared to chemotherapy. An Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy boundary at interim analysis. The safety results of the combination are consistent with those of enfortumab vedotin in combination with pembrolizumab previously reported in cisplatin-ineligible patients with la/mUC.